Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Parchue

Ophthalmology Fort Worth, TX Medical Doctor

NPI 1811993934 CMS profile 173035

1201 Summit Ave, Fort Worth, TX 76102

Open in the dashboard

General payments

$12,744

175 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$117,819 paid to institutions, not to them · program years 2019–2022

Through program year 2025, John Parchue of Fort Worth, TX is reported in the CMS Open Payments database as having received $12,744 across 175 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $117,819 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,448 51
2024 General $2,704 47
2023 General $5,972 25
2022 General $1,151 22
2021 General $74 4
2020 General $334 6
2019 General $1,062 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Parchue
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to John Parchue were reported at $1,448. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year John Parchue Ophthalmology median Middle half National median
2019 $1,062 $258 $104–$655 $163
2020 $334 $126 $45–$321 $114
2021 $74 $205 $76–$534 $132
2022 $1,151 $266 $100–$678 $149
2023 $5,972 $308 $117–$745 $160
2024 $2,704 $340 $127–$846 $164
2025 $1,448 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $7,548 34 payments
  2. Genentech USA, Inc. $808 38 payments
  3. Astellas Pharma US Inc $764 29 payments
  4. Genentech, Inc. $475 4 payments
  5. ANI Pharmaceuticals, Inc. $423 14 payments
  6. Regeneron Pharmaceuticals, Inc. $382 3 payments
  7. Apellis Pharmaceuticals, Inc. $306 5 payments
  8. Novartis Pharmaceuticals Corporation $289 12 payments
  9. AbbVie, Inc. $254 7 payments
  10. Alimera Sciences, Inc. $218 5 payments
  11. Other $1,279 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,392 3 payments
  2. Food and Beverage $6,259 171 payments
  3. Education $93 1 payment
Products named General payments · program years 2019–2025
  1. EYLEA HD $7,402 28 payments
  2. VABYSMO $1,241 40 payments
  3. EYLEA $930 22 payments
  4. Izervay $721 24 payments
  5. SUSVIMO $370 5 payments
  6. ILUVIEN $329 10 payments
  7. YUTIQ $228 9 payments
  8. BEOVU $221 6 payments
  9. ACTHAR $213 2 payments
  10. Clarus 700 $206 1 payment
  11. Other $1,220 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

258

Median for Ophthalmology: 891

Drug cost

$14,064

Median for Ophthalmology: $68,233

Branded share of claims

22.1%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prolensa Bromfenac Sodium Brand 19 $6,606
Prednisolone Acetate Generic 98 $3,594
Atropine Sulfate Generic 55 $1,722
Gatifloxacin Generic 33 $1,499
Erythromycin Erythromycin Base Brand 38 $447
Ofloxacin Generic 15 $196

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$1,065,592

Of which drugs: $859,045

Medicare patients

420

Average age 78

Services billed

13,627

245 women, 175 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 39%
Chronic kidney disease 37%
Ischemic heart disease 29%
Depression 24%
Heart failure 23%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 59 406 $261,112
Injection, faricimab-svoa, 0.1 mg J2777 Office 30 7,920 $216,822
Injection, aflibercept hd, 1 mg J0177 Office 40 808 $212,468
Injection, avacincaptad pegol, 0.1 mg J2782 Office 21 1,340 $115,956
Injection, ranibizumab, 0.1 mg J2778 Office 11 155 $19,446
Injection, bevacizumab, 10 mg J9035 Office 14 32 $1,580

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $1,802
$1,802 — 808
VABYSMO
  • Genentech USA, Inc. $359
$359 — 7,920
Izervay
  • Astellas Pharma US Inc $278
$278 — 1,340
EYLEA
  • Regeneron Healthcare Solutions, Inc. $99
$99 — 406
ILUVIEN
  • Alimera Sciences, Inc. $49
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

175 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record